Treatment(s) already received-Hormonal therapy Posts on Medivizor
Navigation Menu

Treatment(s) already received-Hormonal therapy Posts on Medivizor

Evaluating the effectiveness and safety of ipatasertib plus abiraterone and prednisolone for the treatment of patients with metastatic castration-resistant prostate cancer.

Evaluating the effectiveness and safety of ipatasertib plus abiraterone and prednisolone for the treatment of patients with metastatic castration-resistant prostate cancer.

Posted by on Aug 29, 2021 in Prostate cancer | 0 comments

In a nutshell This study evaluated the effectiveness and safety outcomes of ipatasertib (GDC-0068) in combination with abiraterone acetate (Zytiga) plus prednisone (Deltasone) (AAP) for the treatment of patients with previously untreated metastatic castration-resistant prostate cancer (mCRPC). The data showed that ipatasertib plus...

Read More

Treating castration-resistant prostate cancer that has not spread using new hormonal therapies

Treating castration-resistant prostate cancer that has not spread using new hormonal therapies

Posted by on Aug 15, 2021 in Prostate cancer | 0 comments

In a nutshell This study analyzed the effectiveness and safety of new hormonal therapies (nHTs) in patients with non-metastatic castration-resistant prostate cancer (CRPC). The authors concluded that nHT improved the outcomes of these patients.  Some background CRPC is an aggressive type of prostate cancer that is resistant to androgen...

Read More

Evaluating real-world outcomes of abiraterone and enzalutamide in metastatic castrate-resistant prostate cancer

Evaluating real-world outcomes of abiraterone and enzalutamide in metastatic castrate-resistant prostate cancer

Posted by on Aug 7, 2021 in Prostate cancer | 0 comments

In a nutshell This study compared the real-world outcomes of two widely used drugs, abiraterone (Zytiga) and enzalutamide (Xtandi) in patients diagnosed with metastatic castrate-resistant prostate cancer (mCRPC). The study showed that both drugs were effective in these patients in a real-world setting, with better results...

Read More

Comparing darolutamide with apalutamide and enzalutamide for treating non-metastatic castration-resistant prostate cancer.

Comparing darolutamide with apalutamide and enzalutamide for treating non-metastatic castration-resistant prostate cancer.

Posted by on Jul 17, 2021 in Prostate cancer | 0 comments

In a nutshell The study compared the effectiveness and safety outcomes of darolutamide (Nubeqa) with apalutamide (Erleada) and enzalutamide (Xtandi) in treating non-metastatic castration-resistant prostate cancer (CRPC). The data showed that darolutamide was safer and had similar effectiveness compared to apalutamide and enzalutamide. Some background...

Read More

Evaluating the effectiveness of salvage radiotherapy for recurrence after prostate surgery in patients with localized prostate cancer.

Evaluating the effectiveness of salvage radiotherapy for recurrence after prostate surgery in patients with localized prostate cancer.

Posted by on Jun 30, 2021 in Prostate cancer | 0 comments

In a nutshell This study evaluated the effectiveness of salvage radiotherapy (RT) in patients with recurrence of prostate cancer (PCa) after prostate surgery. The study found that salvage RT was effective in the management of PCa recurrence with manageable side effects. Some background Localized prostate cancer (PCa) is a form of cancer that...

Read More

Analyzing the effectiveness and safety of Lutetium-177–labeled PSMA–targeted therapy in patients with metastatic castration-resistant prostate cancer.

Analyzing the effectiveness and safety of Lutetium-177–labeled PSMA–targeted therapy in patients with metastatic castration-resistant prostate cancer.

Posted by on May 30, 2021 in Prostate cancer | 0 comments

In a nutshell This study reviewed the effectiveness and safety of lutetium-177 [177Lu]-prostate-specific membrane antigen (PSMA)-targeted radioligand therapy (PRLT) for the treatment of patients with metastatic castration-resistant prostate cancer (mCRPC). The data showed that PRLT was associated with good outcomes and manageable side effects. Some...

Read More

Evaluating the combination of sipuleucel-T with radium-223 in men with metastatic castration-resistant prostate cancer spread to the bone.

Evaluating the combination of sipuleucel-T with radium-223 in men with metastatic castration-resistant prostate cancer spread to the bone.

Posted by on May 3, 2021 in Prostate cancer | 0 comments

In a nutshell The study investigated the effectiveness of combining sipuleucel-T (Provenge) with radium-223 (Xofigo) therapy in men with castration-resistant prostate cancer (CRPC) that has spread to the bones. The key finding was that the combination therapy improved the survival rates of these patients.  Some background Prostate cancer often...

Read More

Comparing the activity and safety of [177Lu]Lu-PSMA-617 versus cabazitaxel in patients with metastatic castration-resistant prostate cancer

Comparing the activity and safety of [177Lu]Lu-PSMA-617 versus cabazitaxel in patients with metastatic castration-resistant prostate cancer

Posted by on Apr 10, 2021 in Prostate cancer | 0 comments

In a nutshell This study compared the effectiveness and safety of lutetium-177 [177Lu]-PSMA-617 (177LuPSMA) versus cabazitaxel (Jevtana) for the treatment of patients with metastatic castration-resistant prostate cancer (mCRPC). The data showed that 177LuPSMA treatment showed a higher response with fewer side effects in these patients. Some...

Read More

Evaluating patient-reported outcomes with enzalutamide in the treatment of non-metastatic castration-resistant prostate cancer

Evaluating patient-reported outcomes with enzalutamide in the treatment of non-metastatic castration-resistant prostate cancer

Posted by on Mar 28, 2021 in Prostate cancer | 0 comments

In a nutshell This study evaluated patient-reported outcomes in men with non-metastatic castration-resistant prostate cancer (CRPC) when treated with either enzalutamide (Xtandi) or a placebo. The data showed that enzalutamide treatment delayed the time until pain progression and improved the quality of life of patients compared to a placebo. Some...

Read More

Searching for patients with metastatic breast cancer to trial a targeted therapy

Searching for patients with metastatic breast cancer to trial a targeted therapy

Posted by on Dec 15, 2020 in Breast cancer | 0 comments

In a nutshell This phase 2 clinical trial is evaluating the safety and effectiveness of targeted therapy TAS-120 (futibatinib) alone or in combination with fulvestrant (Faslodex) in patients with metastatic breast cancer (mBC). The main outcomes to be evaluated will be the response rate and survival without cancer worsening. The details Breast...

Read More

Longer-term outcomes for olaparib in the treatment of advanced castration-resistant prostate cancer

Longer-term outcomes for olaparib in the treatment of advanced castration-resistant prostate cancer

Posted by on Oct 24, 2020 in Prostate cancer | 0 comments

In a nutshell This study evaluated longer-term survival rates and the safety of olaparib (Lynparza) in patients with metastatic castration-resistant prostate cancer (mCRPC). It found that treatment with olaparib led to significantly longer survival, especially in men with gene alterations. Some background CRPC is an especially aggressive...

Read More

Quality of life in patients with metastatic prostate cancer under cabazitaxel treatment

Quality of life in patients with metastatic prostate cancer under cabazitaxel treatment

Posted by on Oct 10, 2020 in Prostate cancer | 0 comments

In a nutshell The study compared the quality of life (QoL) of patients with metastatic castration-resistant prostate cancer (mCRPC) treated with cabazitaxel (Jevtana) compared to abiraterone (Zytiga) or enzalutamide (Xtandi). The authors found that cabazitaxel did not reduce QoL in such patients. Some background Patients with mCRPC...

Read More